NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

FDA Approves CARDAMYST: First Self-Administered Nasal Spray for PSVT

Milestone's (MIST) CARDAMYST nasal spray is FDA-approved for adults with PSVT (fast heart rate episodes). It's the first quick, self-administered home treatment.

FDA Approves CARDAMYST: First Self-Administered Nasal Spray for PSVT
Credit: Milestone Pharmaceuticals
Already have an account? Sign in.
12/15/2025 · 5:50 AM
MIST
/ Don’t stop at just one post.

Related↓

Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
04/10/2026 · 7:14 AM

Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)

Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.

/ Subscriber only
/ Read more

Feed↓

Doximity Stock Surges 90% After Strong Q1 Results and AI Progress
Featured/ 08/07/2026 · 6:44 AM

Doximity Stock Surges 90% After Strong Q1 Results and AI Progress

Investors sent Doximity’s stock to the moon after a clean Q1 revenue beat, higher guidance, and clear signs of AI product-market fit.

/ Subscriber only
DraftKings Q2 Results Miss Expectations as World Cup Betting Cuts Into Profits
08/07/2026 · 6:26 AM

DraftKings Q2 Results Miss Expectations as World Cup Betting Cuts Into Profits

DraftKings Q2 revenue fell 5% to $1.44B, missing estimates, as winning bets and promotions weighed on results. Guidance held; handle up 15%.

/ Subscriber only
Twilio Beats Wall Street Estimates, Raises Guidance as Voice AI Takes Off
08/07/2026 · 6:12 AM

Twilio Beats Wall Street Estimates, Raises Guidance as Voice AI Takes Off

Twilio beats expectations with strong Q2 growth, boosted by Voice AI demand, higher customer spending, and raised full-year forecasts.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe